Key result
High rates of reticulated platelets were associated with a significantly higher risk of major adverse cardiovascular and cerebrovascular events (OR 2.67; 95% CI 1.87-3.81) compared to low rates.
Why the study?
Does a high rate of reticulated platelets predict major adverse cardiovascular and cerebrovascular events and cardiovascular mortality in patients with acute and chronic coronary syndromes?
Does a high rate of reticulated platelets predict major adverse cardiovascular and cerebrovascular events and cardiovascular mortality in patients with acute and chronic coronary syndromes?
Odds Ratio: 2.67 (95% CI 1.87–3.81)
Authors
No takes yet. Share an insight, caveat, or question.
Elevated reticulated platelets serve as a promising prognostic biomarker for adverse cardiovascular events and mortality in patients with coronary artery disease, though standardized testing protocols are needed for clinical implementation.
Esteve‐Pastor et al. (2023) conducted an editorial in Acute coronary syndrome (ACS) and chronic coronary syndrome (CCS) (n=2,213). High rate of reticulated platelets vs. Low rate of reticulated platelets was evaluated on Major adverse cardiovascular and cerebrovascular events (OR 2.67, 95% CI 1.87-3.81). High rates of reticulated platelets were associated with a significantly higher risk of major adverse cardiovascular and cerebrovascular events (OR 2.67; 95% CI 1.87-3.81) compared to low rates.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: